Biopharmaceutical firm Atara Biotherapeutics has entered into a clinical trial collaboration agreement with Merck to evaluate the combination of its ATA129 with Keytruda (pembrolizumab) for the treatment of patients with nasopharyngeal carcinoma (NPC) associated with Epstein-Barr virus (EBV).
ATA129 is an investigational, allogeneic EBV-specific cytotoxic T-lymphocytes (CTL), while Merck's Keytruda is an anti-programmed death receptor-1 (anti-PD-1) therapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ATA129 + Keytruda will be assessed in a Phase I/II trial set to begin next year.
Under the agreement, Atara Bio will sponsor the trial, which will include patients with platinum-resistant or recurrent EBV-associated NPC.
Atara Bio chief scientific officer and research and development executive vice-president Chris Haqq said: “Both ATA129 and Keytruda have shown evidence of objective radiographic responses in NPC, and there is a strong biologic rationale to combine these therapies as their complementary mechanisms of action may enhance the anti-tumour activity."
ATA129 induces T-cells to identify EBV antigens that are expressed in the cells of some liquid and solid tumours.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe investigational therapy was previously assessed in Phase I and II trials as a monotherapy in patients with various EBV-positive malignancies.
The trial also included 14 patients with chemotherapy refractory, metastatic NPC and showed that EBV-CTLs expanded after treatment and without the associated lympho-depleting chemotherapy.
According to the data from recent studies, EBV upregulates PD-L1 transcription in related solid tumours such as NPC and gastric cancer, which provides scope for combination with anti-PD-1 therapies.
